Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
The duration of screening within 28 days, treatment 3 weeks/cycle and follow-up 30 days after the last cabazitaxel administration.
Age
20–73
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
I 01. Diagnosis of histologically or cytologically proven prostate adenocarcinoma, that is refractory to hormone therapy (received prior castration by orchiectomy and/or internal medicine, and documented progression of disease or relapse) who has previously been treated with docetaxel.
I 02. Signed informed consent prior to beginning protocol specific procedures.
I 03. Patients with PSA \>20 ng/mL at screening.
You may not be if
E 01. Age \<20 and \>74
E 02. ECOG performance status ≥2.
E 03. Prior surgery ≤4 weeks of registration in the study.
E 04. Active secondary cancer including prior malignancy from which the patient has been disease-free for ≤5 years (However, adequately treated superficial basal cell skin cancer before 4 weeks prior to registration can be eligible to the study)
E 05. Inadequate organ function including:
Neutrophils \<2.0 x 109/L Platelets \<100 x 109/L Hemoglobin \<9.0 g/dL (transfusion prohibition within 14 days before registration) Creatinine \>1.5 mg/dL. Total bilirubin \>1.5 times the upper normal limits of the institutional norms ALT/AST \>1.5 times the upper normal limits of the institutional norms
E 06. Previous treatment with \<225 mg/m2 cumulative dose of Taxotere® (or docetaxel).
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Clareo Health | Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
